Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Namodenoson - Can-Fite Biopharma

Drug Profile

Namodenoson - Can-Fite Biopharma

Alternative Names: CF-102; Cl-IB-MECA; Namodenoson

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Can-Fite BioPharma; Rabin Medical Center; Temple University School of Medicine
  • Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Iodobenzenes; Obesity therapies; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Colorectal cancer; Hepatic fibrosis; Malignant melanoma; Obesity; Prostate cancer; Reperfusion injury
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 05 Nov 2019 Can-Fite BioPharma announces intention to submit NDA to the US FDA for Liver cancer
  • 05 Nov 2019 Can-Fite BioPharma initiates an compassionate use programme for Liver cancer
  • 01 Nov 2019 Can Fite BioPharma plans a phase III trial for Liver cancer (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top